The improvement of malnutrition with levocarnitine in maintenance hemodialysis patients is controversial. We performed a meta-analysis to evaluate the efficacy of levocarnitine in improving malnutrition in maintenance hemodialysis patients. We performed a literature search for relevant articles related to the treatment of malnutrition by L-carnitine in maintenance hemodialysis patients in PubMed, Embase, Web of Science, China National Knowledge Infrastructure, and Wanfang databases. We set the publication dates from 1950 to July 2019. The levels of albumin, prealbumin, total protein, and transferrin before and after treatment were used for assessing malnutrition. Twenty-seven studies were included in the present analysis. The results of the random-effects model indicated that L-carnitine treatment improved the albumin level in patients on maintenance hemodialysis patients. The pooled standardized mean difference of albumin level was 2.51 (95% confidence interval (CI): 2.13−2.90, P<0.001). The pooled total protein level was 3.83 (95% CI: 2.41−5.24, P=0.000) and the pooled transferrin level was 0.35 (95% CI: 0.18−0.52, P=0.000). Significant differences were observed with the total protein and transferrin levels. The results indicated that levocarnitine significantly improved the prealbumin level in patients on maintenance hemodialysis. The pooled prealbumin level was 70.86 (95% CI: 42.99−98.73, P=0.000). No publication bias was detected (P>0.05). The present meta-analysis indicated that L-carnitine can have a favorable effect on malnutrition biomarkers in patients on maintenance hemodialysis, including the increase in albumin, total protein, transferrin, and prealbumin levels. The L-carnitine could be an option for treatment of MHD patients.